Introduction
============

Liver cancer is a malignant cancer with poor prognosis that is responsible for more than 780,000 deaths annually, making it the second most common cause of cancer-related mortality worldwide ([@ref-4]). Although liver cancer can be alleviated or cured through hepatectomy, orthotopic liver transplantation, and/or ablative procedures ([@ref-16]). More than 65% of patients fail to be cured and frequent recurrence contributes to poor survival. Predicting the overall 1-year survival rates for liver cancer have remained a challenge ([@ref-12]; [@ref-16]). New biomarkers that can predict liver cancer recurrence are urgently required to improve prognosis.

Liver cancer is influenced by post-transcriptional mechanisms that dynamically regulate protein expression ([@ref-39]; [@ref-14]). Cis-regulatory RNA elements and trans-acting factors ([@ref-13]; [@ref-29]) including RNA-binding proteins (RBPs) play an essential role in gene expression in cancer cells ([@ref-28]). Recently, a group of RBPS termed MEX-3 RNA binding family member (MEX3) was identified in the nematode Caenorhabditis elegans ([@ref-7]) and revealed one of the few RBPs with carcinogenic or tumor suppressor activity ([@ref-25]; [@ref-30]).

MEX3 proteins are evolutionarily conserved RNA-binding proteins that consist of four homologous genes (MEX3A--D) ([@ref-5]; [@ref-9]; [@ref-30]). They contained highly conservative one carboxy-terminal RING finger module and two K homology domains, the former mediating E3 ubiquitin ligase activity, the latter providing RNA-binding capacity ([@ref-5]). Available evidence implicates the MEX3 family in epithelial homeostasis, embryonic development, metabolism, immune responses and cancer, but the specific mechanisms of these effects require elucidation ([@ref-30]). MEX3A is a member of the MEX3 family (also known as RKHD4 or RNF162) that is expressed in endometrium tissue and the ovaries. MEX3A is a novel component of GW-182 or Dcp-containing bodies in mammals that represent cellular sites of mRNA degradation and the sequestration of non-translated transcripts ([@ref-8]; [@ref-10]; [@ref-34]).

MEX3A mRNA was recently shown to be overexpressed in Wilms tumors ([@ref-26]), gastric cancer ([@ref-19]), bladder cancer ([@ref-18]), and bladder urothelial carcinoma ([@ref-35]). MEX3A promotes cell proliferation in bladder ([@ref-18]) and gastric ([@ref-19]) cancer and shows potential as a biomarker to predict carcinogenesis ([@ref-30]). In this study, we analyzed the expression of MEX3A in liver cancer and assessed its clinicopathological potential. We further investigated the potential of MEX3A as an independent predictor of liver cancer prognosis.

Methods
=======

Clinical and RNA-Seq analysis
-----------------------------

We downloaded the all RNA-Seq expression matrix from the Cancer Genome Atlas (TCGA) database and obtained MEX3A mRNA expression data from liver cancer vs. normal liver tissue using the matrix. We further obtained corresponding clinical and pathological information from TCGA database. The basic clinical data included age, gender, histological grade, stage, *T*∕*N*∕*M* classification and vital status. MEX3A mRNA expression were estimated as log2(x+1) values and transformed RSEM normalized counts.

Statistical analyses
--------------------

We retrospectively analyzed all data using R (version 3.5.1) ([@ref-32]). We used non-parametric rank sum tests to analyze MEX3A mRNA expression levels according to different variables and boxplots were visualized. Wilcoxon rank sum tests were used to compare the two subgroups, including disease, age, gender and vital status. Kruskal--Wallis tests were used for the comparison of three or more subgroups, including clinical stage, histologic grade and *T*∕*N*∕*M* classification. We used the pROC package to draw ROC curves for the evaluation of MEX3A diagnosis through the calculation of AUC values and the measurement of optimal cutoff point to divide samples into high and low MEX3A expression groups ([@ref-33]). Further, correlation between clinical features and MEX3A expression group were analyzed through chi-square tests with Fisher's exact test.

To evaluate prognosis, Kaplan--Meier curves were used based on log-rank tests to compare differences in survival status, including overall survival (OS) and relapse-free survival (RFS) between the high and low MEX3A expression groups using the survival package in R ([@ref-37]; [@ref-38]). Univariate Cox analysis was used to select factors associated with prognosis, with calculations of hazard ratios (HRs) and 95% confidence intervals (95% CIs). Independent prognostic values of OS and RFS in the patients were determined through Multivariate Cox analysis. *P*-values \< 0.05 were deemed statistically significant.

Results
=======

Clinical characteristics and RNA-Seq analysis
---------------------------------------------

A total of 423 tissue samples with MEX3A mRNA expression data, including 373 liver cancer and 50 normal liver tissues were obtained from the TCGA. All patients were diagnosed with primary liver cancer. Corresponding patient demographic and clinical characteristics such as age, gender, histologic grade, TNM stage, vital status, and radiation therapy were obtained. All patient data is shown in [Table 1](#table-1){ref-type="table"}.
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###### MEX3A mRNA expression and clinical characteristics in liver cancer patients.
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  Characteristics                    Number of pts(%)
  ---------------------------------- ------------------
  Age                                
  \<55                               117(31.45)
  \>=55                              255(68.55)
  NA                                 1(0.00)
  Gender                             
  Female                             121(32.44)
  Male                               252(67.56)
  Histological_type                  
  Fibrolamellar Carcinoma            3(0.8)
  Hepatocellular Carcinoma           363(97.32)
  Hepatocholangiocarcinoma (Mixed)   7(1.88)
  Histologic_grade                   
  G1                                 55(14.75)
  G2                                 178(47.72)
  G3                                 123(32.98)
  G4                                 12(3.22)
  NA                                 5(1.34)
  Stage                              
  I                                  172(46.11)
  II                                 87(23.32)
  III                                85(22.79)
  IV                                 5(1.34)
  NA                                 24(6.43)
  T_classification                   
  T1                                 182(48.79)
  T2                                 95(25.47)
  T3                                 80(21.45)
  T4                                 13(3.49)
  TX                                 1(0.27)
  NA                                 2(0.54)
  N_classification                   
  N0                                 253(67.83)
  N1                                 4(1.07)
  NX                                 115(30.83)
  NA                                 1(0.27)
  M_classification                   
  M0                                 267(71.58)
  M1                                 4(1.07)
  MX                                 102(27.35)
  Radiation_therapy                  
  No                                 340(91.15)
  Yes                                8(2.14)
  NA                                 25(6.7)
  Residual_tumor                     
  R0                                 326(87.4)
  R1                                 17(4.56)
  R2                                 1(0.27)
  RX                                 22(5.9)
  NA                                 7(1.88)
  Vital_status                       
  Deceased                           130(34.85)
  Living                             243(65.15)
  Relapse                            
  No                                 179(55.94)
  Yes                                141(44.06)
  NA                                 53(14.2)
  MEX3A                              
  High                               117(31.37)
  Low                                256(68.63)

**Notes.**

NA, not available.

MEX3A is highly expressed in liver cancer
-----------------------------------------

In liver cancer, MEX3A mRNA expression level was significantly up-regulated compared to normal tissues (*p* = 1.1e−14; [Fig. 1A](#fig-1){ref-type="fig"}) and increased with higher histological grades (*p* = 0.00016; [Fig. 1C](#fig-1){ref-type="fig"}). MEX3A expression level was significantly associated with vital status (*p* = 0.032; [Fig. 1I](#fig-1){ref-type="fig"}) and age (*p* = 0.0011; [Fig. 1G](#fig-1){ref-type="fig"}).

![Assessment of the relationship between MEX3A mRNA expression and clinical characteristics (A--I).\
Comparison of MEX3A mRNA expression in 373 cases of liver cancer and 50 normal liver tissues (A). Comparison of MEX3A mRNA expression according to clinical parameters: clinical stage (I, II, III and IV) (B), histologic grade (G1, G2, G3 and G4) (C), T classification (T1, T2, T3 and T4) (D), N classification (N0, N1 and NX) (E), M classification (M0, M1 and MX) (F), age (\<55 and ≥55) (G), gender (male and female) (H) and vital status (I).](peerj-08-8252-g001){#fig-1}

MEX3A as a liver cancer diagnostic.
-----------------------------------

ROC curve analysis showed that MEX3A had moderate diagnostic ability in patients with liver cancer (AUC=0.837; [Fig. 2A](#fig-2){ref-type="fig"}). The diagnostic ability of MEX3A was comparable in all clinical stages (stage I: AUC = 0.823, stage II: AUC = 0.844, stage III: AUC = 0.835, stage IV: AUC = 0.888; [Figs. 2B](#fig-2){ref-type="fig"}--[2E](#fig-2){ref-type="fig"}).

![ROC analysis of the sensitivity and specificity of MEX3A to assess liver cancer.\
ROC curve for MEX3A expression in normal liver tissue and tumor tissue: AUC = 0.837 (A). I stage patients: AUC = 0.823 (B). II stage patients: AUC = 0.844 (C). III stage patients: AUC = 0.835 (D). IV stage patients: AUC = 0.888 (E). Abbreviations: AUC, area under the curve; ROC, receiver-operating characteristics.](peerj-08-8252-g002){#fig-2}

Relationship between MEX3A expression and clinical characteristics
------------------------------------------------------------------

[Figure S1](#supp-1){ref-type="supplementary-material"} showed that the cutoff point was 7.266 when samples were divided according to high and low MEX3A expression. Chi-square tests were used to analyze clinical variables between the two groups, in which high MEX3A expression was associated with cancer related mortality (*p* = 0.001; [Table 2](#table-2){ref-type="table"}). High MEX3A expression was also associated with a deterioration in liver tumor histopathology (*p* \< 0.001; [Table 2](#table-2){ref-type="table"}).

10.7717/peerj.8252/table-2

###### Association between MEX3A expression and clinical characteristics in liver cancer patients.
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  Clinical characteristics                                            MEX3A expression                                   
  -------------------------- ---------------------------------- ----- ------------------ ------- ----- ------- --------- -----------
  Age                        \<55                               117   51                 43.59   66    25.88   10.8573   **0.001**
                             \>=55                              255   66                 56.41   189   74.12             
  Gender                     Female                             121   43                 36.75   78    30.47   1.1741    0.279
                             Male                               252   74                 63.25   178   69.53             
  Histological type          Fibrolamellar Carcinoma            3     0                  0       3     1.17    1.8006    0.547
                             Hepatocellular Carcinoma           363   114                97.44   249   97.27             
                             Hepatocholangiocarcinoma (Mixed)   7     3                  2.56    4     1.56              
  Histologic grade           G1                                 55    10                 8.7     45    17.79   20.0434   **0.000**
                             G2                                 178   48                 41.74   130   51.38             
                             G3                                 123   48                 41.74   75    29.64             
                             G4                                 12    9                  7.83    3     1.19              
  stage                      I                                  172   48                 43.64   124   51.88   2.1216    0.512
                             II                                 87    30                 27.27   57    23.85             
                             III                                85    30                 27.27   55    23.01             
                             IV                                 5     2                  1.82    3     1.26              
  T classification           T1                                 182   49                 41.88   133   52.36   4.9613    0.253
                             T2                                 95    35                 29.91   60    23.62             
                             T3                                 80    27                 23.08   53    20.87             
                             T4                                 13    6                  5.13    7     2.76              
                             TX                                 1     0                  0       1     0.39              
  N classification           N0                                 253   86                 73.5    167   65.49   3.4688    0.135
                             N1                                 4     2                  1.71    2     0.78              
                             NX                                 115   29                 24.79   86    33.73             
  M classification           M0                                 267   88                 75.21   179   69.92   2.0953    0.304
                             M1                                 4     2                  1.71    2     0.78              
                             MX                                 102   27                 23.08   75    29.3              
  radiation therapy          NO                                 340   106                98.15   234   97.5    0         1.000
                             Yes                                8     2                  1.85    6     2.5               
  Residual tumor             R0                                 326   97                 84.35   229   91.24   5.1533    0.134
                             R1                                 17    7                  6.09    10    3.98              
                             R2                                 1     0                  0       1     0.4               
                             RX                                 22    11                 9.57    11    4.38              
  Vital status               Deceased                           130   55                 47.01   75    29.3    10.3281   **0.001**
                             Living                             243   62                 52.99   181   70.7              

**Notes.**

\% represents the distribution of different clinical features in the single MEX3A expression group *P*-value in bold represent significant clinical significance (*p* \< 0.05).

MEX3A is an independent prognostic to evaluate the survival of liver cancer patients
------------------------------------------------------------------------------------

Kaplan--Meier curves showed that patients with high MEX3A expression were more likely to have a poor OS (*p* \< 0.0001; [Fig. 3A](#fig-3){ref-type="fig"}). Further subgroup analysis showed that high MEX3A expression was associated with poor OS for all variables: stage I/II (*p* = 0.0011; [Fig. 3B](#fig-3){ref-type="fig"}), stage III/IV (*p* = 0.00022; [Fig. 3C](#fig-3){ref-type="fig"}), stage G1/G2 (*p* \< 0.0001; [Fig. 3D](#fig-3){ref-type="fig"}), stage G3/G4 (*p* = 0.044; [Fig. 3E](#fig-3){ref-type="fig"}), male (*p* \< 0.0001; [Fig. 3F](#fig-3){ref-type="fig"}), female (*p* = 0.0066; [Fig. 3G](#fig-3){ref-type="fig"}), younger (*p* = 0.0026; [Fig. 3H](#fig-3){ref-type="fig"}), older (*p* = 0.00022; [Fig. 3I](#fig-3){ref-type="fig"}). Through Univariate and Multivariate Cox analysis of OS, MEX3A (HR = 2.26, 95% CI \[1.58--3.23\], *p* \< 0.0001) was identified as an independent risk factor for the prognosis of liver cancer along with T stage (*p* \< 0.0001) and residual tumors (*p* = 0.026; [Table 3](#table-3){ref-type="table"}).

![Analysis of OS between high and low expression groups of MEX3A according to the different clinical variables of liver cancer patients.\
Kaplan-Meier curves of OS in all patients with liver cancer (A). Subgroup analysis was performed in stage I/II (B), stage III/IV (C), histological grade G1/G2 (D), histological grade G3/G4 (E), males (F), females (G), young patients (H) and old patients (I).](peerj-08-8252-g003){#fig-3}
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###### Relationship between clinical parameters, MEX3A mRNA expression and overall survival in liver cancer patients.
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                      Univariate analysis   Multivariate analysis                               
  ------------------- --------------------- ----------------------- ------- ------ ------------ -----------
  Age                 1.00                  0.69--1.45              0.997                       
  Gender              0.80                  0.56--1.14              0.220                       
  Histological type   0.99                  0.27--3.66              0.986                       
  Histologic grade    1.04                  0.84--1.3               0.698                       
  Stage               1.38                  1.15--1.66              0.001   0.86   0.69--1.07   0.163
  T classification    1.66                  1.39--1.99              0.000   1.88   1.48--2.38   **0.000**
  N classification    0.73                  0.51--1.05              0.086                       
  M classification    0.72                  0.49--1.04              0.077                       
  Radiation therapy   0.51                  0.26--1.03              0.060                       
  Residual tumor      1.42                  1.13--1.8               0.003   1.33   1.03--1.71   **0.026**
  MEX3A               2.29                  1.61--3.26              0.000   2.26   1.58--3.23   **0.000**

**Notes.**

*P*-value in bold represent significant clinical significance (*p* \< 0.05)

Based on the OS, we further explored the connection between RFS and MEX3A expression, and found that high MEX3A expression was associated with poor RFS (*p* \< 0.0001; [Fig. 4A](#fig-4){ref-type="fig"}). RFS was related to the expression of MEX3A for some variables, including stage I/II (*p* = 0.013; [Fig. 4B](#fig-4){ref-type="fig"}), stage III/IV (*p* = 0.00027; [Fig. 4C](#fig-4){ref-type="fig"}), stage G1/G2 (*p* \< 0.0001; [Fig. 4D](#fig-4){ref-type="fig"}), male (*p* = 0.0023; [Fig. 4F](#fig-4){ref-type="fig"}), female (*p* = 0.0049; [Fig. 4G](#fig-4){ref-type="fig"}), younger (*p* = 0.0025; [Fig. 4H](#fig-4){ref-type="fig"}) and older (*p* = 0.0047; [Fig. 4I](#fig-4){ref-type="fig"}). Univariate and Multivariate Cox analysis suggested that MEX3A (HR = 2.19, 95% CI \[1.54--3.12\], *p* \< 0.0001) was an independent risk factor to evaluate the RFS for liver cancer along with T stage (*p* \< 0.0001) and residual tumor status (*p* = 0.024; [Table 4](#table-4){ref-type="table"}).

![Analysis of RFS in high and low MEX3A expression groups according to the clinical variables of liver cancer patients.\
Kaplan-Meier curves of RFS in all patients with liver cancer (A). Subgroup analysis was performed in stage I/II (B), stage III/IV (C), histological grade G1/G2 (D), histological grade G3/G4 (E), males (F), females (G), young patients (H) and old patients (I).](peerj-08-8252-g004){#fig-4}

Discussion
==========

Liver cancer is one of the deadliest tumors worldwide. The main risk factors for liver cancer include hepatitis B or C virus infections, the intake of aflatoxin, alcohol abuse and non-alcoholic fatty liver disease (NAFLD) ([@ref-40]). Due to the lack of effective diagnostic and prognostic evaluation methods, the mortality rates of liver cancer patients have gradually increased. New molecular markers that can guide prognosis and improve the survival rates of liver cancer patients are urgently required. Our team has devoted to exploring diagnostic and prognostic biomarkers in various cancers ([@ref-17]; [@ref-20]; [@ref-21]; [@ref-22]; [@ref-23]; [@ref-24]; [@ref-27]; [@ref-36]). In this study, MEX3A mRNA was identified as overexpressed in liver cancer tissue and could effectively evaluate the prognosis of liver cancer patients as an independent predictor. A strong correlation between high MEX3A expression and liver malignancy was also observed.

MEX3A is known to be upregulated in Wilms renal cancer ([@ref-26]), gastric cancer ([@ref-19]), bladder cancer ([@ref-18]) and bladder urothelial cancer ([@ref-35]). These results are consistent with our finding that MEX3A mRNA is overexpressed in liver cancer (*p* = 1.1e^−14^). Area under the ROC curves was 0.837, which provided evidence that MEX3A was a potential biomarker for liver cancer diagnosis. Interestingly, the expression of MEX3A was higher with increased histological grade (*p* \< 0.0001), suggesting that MEX3A is related to tumor progression.

The molecular mechanism underlying the oncogenic effects of MEX3A remain poorly understood. [@ref-18] found that MEX3A silencing significantly inhibits the proliferation of bladder cancer cells and promotes apoptosis. Jiang et al. similarly reported that MEX3A silencing delays the cell cycle progression of gastric cancer cells. MEX3A silencing significantly inhibited cell migration and anchorage-independent growth ([@ref-19]). In colorectal cells, MEX3A is a stemness-related gene ([@ref-1]; [@ref-6]; [@ref-11]) that acts as a repressive factor through controlling the expression of CDX2. CDX2 inhibits colorectal tumor cells growth, invasion, progression and migration and plays an essential regulatory role in intestinal homeostasis ([@ref-2]; [@ref-3]; [@ref-15]; [@ref-31]). If MEX3A is overexpressed in colonic cell lines, cell polarity and differentiation become impaired leading to carcinogenesis ([@ref-31]). Combined with our findings, the role of MEX3A in cancer progression explains its clinical links to poor histological grade and poor patient prognosis in liver cancer. It is therefore necessary to explore the relationship between MEX3A and survival.

The MEX3 family shows promise as a biomarker for both cancer progression and prognosis ([@ref-30]). However, in studies by Huang et al. ([@ref-35]), no prognostic significance for cancer bladder urothelial carcinoma samples following MEX3A overexpression were observed. These results contrasted our findings and may highlight differential roles of MEX3A in cancer progression according to cancer-type. Of note, upon assessment of each sub-variable group, Kaplan--Meier curves revealed that the liver cancer patients with high MEX3A expression had a poor OS. RFS were evaluated according to MEX3A expression and showed a similar relationship with OS, excluding G3/G4 group. This highlights the unique superiority of MEX3A expression for the assessment of liver cancer survival. In particular, as shown in [Tables 3](#table-3){ref-type="table"} and [4](#table-4){ref-type="table"}, MEX3A may represent a prognostic marker for liver cancer survival (OS and RFS) under the strong confounding effects of clinicopathological features, providing useful references for clinicians to aid the development of individualized patient's treatments.

In summary, this is the first study to report the association between MEX3A mRNA and the clinical characteristics and survival of liver cancer patients. MEX3A has great potential to predict the prognosis of liver cancer patients. Future studies should explore the mechanisms by which MEX3A promotes liver cancer *in vivo* and *in vitro*. Further clinicopathological information and corresponding clinical tissue samples should be obtained to further validate these findings and to establish MEX3A as a novel prognostic for patients with liver cancer.
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###### Relationship between clinical parameters, MEX3A mRNA expression and relapse-free survival in liver cancer patients.
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                      Univariate analysis   Multivariate analysis                               
  ------------------- --------------------- ----------------------- ------- ------ ------------ -----------
  Age                 0.90                  0.63--1.28              0.550                       
  Gender              0.99                  0.7--1.41               0.966                       
  Histological type   2.02                  0.66--6.24              0.220                       
  Histologic grade    0.98                  0.8--1.21               0.883                       
  Stage               1.66                  1.38--1.99              0.000   1.13   0.87--1.46   0.358
  T classification    1.78                  1.49--2.12              0.000   1.69   1.29--2.21   **0.000**
  N classification    0.97                  0.67--1.4               0.874                       
  M classification    1.17                  0.79--1.74              0.432                       
  Radiation therapy   0.74                  0.26--2.16              0.584                       
  Residual tumor      1.28                  1.01--1.61              0.042   1.32   1.04--1.67   **0.024**
  MEX3A               2.05                  1.46--2.9               0.000   2.19   1.54--3.12   **0.000**

**Notes.**

*P*-value in bold represent significant clinical significance (*p* \< 0.05).

Conclusions
===========

This is the first study to investigate the expression of MEX3A mRNA in liver cancer, revealing its association with specific clinical features. Moreover, our results indicate that MEX3A plays a significant role in the prognosis of liver cancer and can be used as an independent factor to predict liver cancer progression.

Supplemental Information
========================
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###### Optimal cutoff points for dividing patients into high and low MEX3A expression groups identified through ROC curves

###### 

Click here for additional data file.
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